Merck has shared these additional analyses with the FDA and they will be presented to the FDA’s Antimicrobial Drugs Advisory Committee on Nov. 30th
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
The approval is for Cytomegalovirus, a type of Herpes virus
Jardiance is the first SGLT2-inhibitor therapy to prove reduction in risk of cardiovascular death in people with type-II diabetes and established cardiovascular disease
Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC
Achondroplasia is a genetic condition that causes severely short stature and disproportionate growth
The nutraceutical sector is on the cusp of exponential growth and Covid-19 has accelerated the pace of its applications. Dr R.B Smarta, CMD, Interlink, shares his perspective on the growth opportunities and challenges for the sector
The final data from the trial showed sotrovimab reduces hospitalisation and risk of death by 79% in adults with mild-to-moderate Covid-19 who are at high risk of progression to severe disease
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
If approved or authorized, Paxlovid would be the first oral antiviral of its kind, to combat SARS-CoV-2
Subscribe To Our Newsletter & Stay Updated
